Major trial aims to tame leukemia with new drugs, reduce need for harsh transplants
NCT ID NCT06860269
Summary
This large study aims to improve treatment for adults with acute lymphoblastic leukemia (ALL), a fast-growing blood cancer. It will test whether adding new, targeted immunotherapy drugs to standard treatment can better control the disease and reduce the need for stem cell transplants in the first remission. The trial will enroll about 1200 adults aged 18-65 with newly diagnosed ALL to compare different treatment approaches across three main patient groups.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hôpital Saint Louis
RECRUITINGParis, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.